Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript

SA Transcripts158.97K FollowersFollow5ShareSaveCommentsQ4: 2026-03-12 Earnings SummaryInsightsTranscript InsightsPlay CallPlay CallTranscriptEPS of $0.24 beats by $0.32 | Revenue of $104.24M (586.46% Y/Y) beats by $68.29M Vaxart, Inc. (VXRT) Shareholder/Analyst Call March 13, 2026 4:30 PM EDT Company Participants Steven Lo - President, CEO & DirectorJames Cummings - Chief Medical OfficerSean Tucker - Senior VP & Chief Scientific OfficerJeroen Grasman - CFO, Principal Accounting Officer & Principal Financial OfficerEdward Berg - Senior VP & General Counsel Conference Call Participants David Carey - Finn Partners, Inc.

Presentation Operator Greetings, and welcome to Vaxart's Stockholder Fireside Chat Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the webcast over to David Carey, Finn Partners. David CareyFinn Partners, Inc. Good afternoon, and welcome to today's call. Joining us from Vaxart are Steve Lo, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr. James S. Cummings, Chief Medical Officer; Jeroen Grasman, Chief Financial Officer; and Ed Berg, Senior Vice President and General Counsel. Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, any partnerships with third parties, timing of any anticipated regulatory approvals or that any such approval will be obtained, the company's future cash runway, ability to regain compliance with NASDAQ listing standards or raise capital if such listing is regained, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials. Actual results could materially differ from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process and other risks described in the Risk Factors section of Vaxart's most recently filed annual report on Form 10-K and also on other periodic reports filed with the SEC. Vaxart undertakes no obligation to update